bld-2660
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2018 (NCT03559166)
Timeline
Indications
Mechanism of action
- Calpain 1INHIBITOR
CAPN1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bld-2660
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04334460 | Phase 2 | May 31, 2020 | Blade Therapeutics |
| NCT04244825 | Phase 2 | Apr 30, 2020 | Blade Therapeutics |
| NCT04001998 | Phase 1 | Aug 31, 2019 | Blade Therapeutics, Scientia Clinical Research Limited Sydney |
| NCT03559166 | Phase 1 | Jun 30, 2018 | Blade Therapeutics, Nucleus Network Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blade Therapeutics | For profit | 4 | 4 | 2 | 2018 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2018 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1